Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Diagnostic Procedures Following Lung Cancer Screens with non-Cancer Abnormalities

Principal Investigator
Name
Lois Lamerato
Institution
Henry Ford Health System
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2006-0315
Initial CDAS Request Approval
Jul 1, 2006
Title
Diagnostic Procedures Following Lung Cancer Screens with non-Cancer Abnormalities
Summary
We propose here to utilize the data base of the Henry Ford Health System (HFHS) to collect information on diagnostic procedures undertaken following all screens among a sample of HFHS Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) subjects enrolled at HFHS. The non-lung cancer outcomes, such as cardiac disease, will be investigated to determine whether participation in a cancer screening trial is associated with a higher medical costs unrelated to lung cancer detection and care.
Aims

1. To determine the rates of various follow-up diagnostic procedures in the periods before and after various screening results, with the emphasis on specific abnormal, not suspicious for lung cancer, findings (e.g., COPD, scarring, cardiac abnormalities). 2. To ascertain whether rates for certain procedures are increased in the period after a given abnormal, not suspicious for lung cancer, screening result as compared to the period after a negative screening result or as compared to the period before the abnormal, not suspicious for lung cancer, screening result. 3. To estimate medical costs in the periods before and after various abnormal, not suspicious for lung cancer, screening results as compared to comparable periods before and after negative screens.